Rakovina Therapeutics expands Variational AI pact, gains exclusivity on kt-5000 ATR inhibitor target profile
Bitget2026/10/14 09:30- Rakovina Therapeutics amended, extended its research services deal with Variational AI for the kt-5000 ATR inhibitor program.
- Amendment grants exclusivity on a defined target product profile covering potency, selectivity, drug-like properties, brain penetration for the agreed term.
- Variational AI to run additional Enki lead-optimization cycles beyond five already delivered at no added cost to Rakovina.
- Variational AI to receive higher milestone payments tied to drug-candidate nomination, completion of an out-licensing transaction.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
